Shares ntawm Turning Point Therapeutics Inc (NASDAQ: TPTX) ntau dua ob npaug rau hnub Friday tom qab Bristol-Myers Squibb Co (NYSE: BMY) hais tias nws yuav yuav lub tuam txhab biotech rau $ 4.10 nphom nyiaj ntsuab.
Bristol-Myers them $76 ib feem rau TPTX
Cov kws kho mob loj yog them $ 76 ib feem rau Turning Point uas sawv cev rau 116% tus nqi ntawm tus nqi uas TPTX kaw qhov kev sib tham tsis tu ncua rau hnub Thursday.
Raws li bristol-myers, nws yuav siv nyiaj ntawm tes los ua kom tau nyiaj kom txog thaum 2025 kom muaj kev ua kom txog rau nws cov nyiaj tau los-gaap rau txoj kev khwv nyiaj. BMY yog nyob ze rau hnub Friday.
Cov xov xwm tuaj txog lub lis piam tom qab Turning Point Therapeutics Inc tau tshaj tawm dav dua-qhov kev cia siab rau ib qho kev poob rau nws cov nyiaj txiag thawj peb lub hlis twg.
Deal yuav kaw nyob rau lub quarter thib peb ntawm 2022
Ob leeg Bristol-Myers thiab Turning Point twb tau txais kev pom zoo los ntawm lawv pawg thawj coj. Kev lag luam yuav tsum ua kom tiav hauv peb lub hlis twg ntawm 2022, raws li kev cai kaw.
TPTX Pawg Thawj Coj tau pom zoo kom cov tswv lag luam lees txais qhov kev sib tw. Hauv xovxwm tso tawm tag kis no, Turning Point Therapeutics Inc CEO Athena Countouriotis tau hais tias:
Nrog Bristol Myers 'kev coj noj coj ua hauv oncology, muaj peev xwm ua lag luam muaj zog thiab tsim cov hneev taw, peb yuav muaj peev xwm ua kom nrawm dua qhov uas peb tuaj yeem nqa peb cov tshuaj tshiab los pab cov neeg kuaj mob qog noj ntshav.
Tus ncej Turning Point Therapeutics sib koom ntau dua ob npaug rau hnub Friday tshwm sim thawj zaug Tsam.
Tau qhov twg los: https://invezz.com/news/2022/06/03/turning-point-therapeutics-shares-more-than-doubled-on-friday/